Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified N-acyl arylsulfonamides, particularly N-(Boc-piperidine-4-carbonyl)-benzenesulfonamides, as steroid sulfatase inhibitors with improved cellular potency compared to previous compounds.

In this study, researchers found that cepharanthine significantly inhibited HSV-1 replication in vitro by interfering with specific signaling pathways, arresting the cell cycle, and inducing apoptosis in infected cells, highlighting its potential as an antiviral agent.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

In this case study, hypertrichosis in a patient with hemophilia and hepatitis C may have been induced by IFN-alpha treatment, despite the drug usually causing hair loss.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This report describes the first case of hair loss in a patient on ritonavir-boosted atazanavir therapy for HIV, with hair regrowth following a switch to a non-protease inhibitor regimen.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

Raltegravir may cause hair loss in some patients.

This article discusses a case of delayed onset perforating folliculitis linked to the use of sorafenib, but it reports no new clinical results.

This observational study suggests that antiretroviral drugs that interact with CYP 3A4 enzymes may alter finasteride's effectiveness for hair loss in men treated for HIV.

In this study, isatin-gallate hybrids were synthesized and assessed, with compound 3b showing significant in vitro antioxidant and cytotoxic activities, and the series displaying moderate efficacy in inhibiting coronavirus activity through in silico analysis.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

This article discusses the potential of intralesional cidofovir as a treatment for SCC and reports no systemic toxicity, but highlights surgical excision as the most reliable curative option.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

In this bibliometric study, researchers analyzed 96 publications from 2000 to 2022 to identify trends in HIV-1 capsid inhibitor research, highlighting the USA as a leading contributor and emphasizing the importance of molecular studies and drug discovery in advancing antiretroviral therapy.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

In this study, mild adverse reactions to COVID-19 vaccines were reported among vaccinated staff and students, with females experiencing more reactions than males.

This review concluded that monoclonal antibodies are currently the most effective treatment for COVID-19, with potential efficacy of high-titer convalescent plasma when used early, while multiple other drugs require further evaluation to determine their effectiveness.

In this study, 90 pediatric patients with scalp microsporia were treated with a combination of griseofulvin, Antral, sertaconazole nitrate cream, and Bion 3 Kid, resulting in complete recovery, reduced treatment duration, and prevention of disease recurrence and colds, with high drug tolerability.

This correspondence reported significant variability between quantitative PCR and bDNA assays for measuring Hepatitis C virus RNA in high-titer specimens, challenging the reliability of the Chiron assay.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

This study found that for metastatic colorectal cancer patients, substituting calcium folinate with disodium folinate in combination with fluorouracil and oxaliplatin showed similar effectiveness and safety as the mFOLFOX6 regimen.

This study observed that patients who received Favipiravir treatment after having COVID-19 had lower positive pull test scores for telogen effluvium hair loss compared to those who did not, suggesting that Favipiravir may not influence the development of telogen effluvium.

This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.

This review outlines the urgent need for effective therapeutic interventions against coronaviruses, as current vaccines are challenged by virus mutations, and emphasizes developing safe, affordable, and broad-spectrum antivirals for both human and porcine coronaviruses.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.